[The effects of resuscitation with hypertonic saline solution on the postburn pulmonary injury in scalded dogs].
OBJECTIVE
To explore the preventive and curative effects of resuscitation with hypertonic saline solution on postburn pulmonary injury in scalded dogs.


METHODS
Mongrel dogs inflicted by 40% TBSA III degree scald were employed as the model. Sixteen dogs were randomly divided into two groups with 8 in each group, i.e. hypertonic saline solution group (H group) and isotonic saline solution (N group). The changes in cardiac output (CO), cardiac index (CI), pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) were determined within 48 postburn hours (PBHs). Pulmonary tissue samples were obtained for the measurement of pulmonary water and hydrocarbon (C2 H4 and C2 H6) contents. Bronchoalveolar lavage fluid (BALF) was harvested for white blood cell (WBC) counting and classification and for the detection of the changes in PLA2 activity and LTC4 content.


RESULTS
Compared to those in N group, the CO and CI in H group increased significantly while the pulmonary water content, the hydrocarbon content, the WBC count, and PLA2 activity and LTC4 content in BALF all decreased obviously.


CONCLUSIONS
Hypertonic saline solution might be beneficial in the management of early postburn pulmonary injury.
Wang
J
J
Institute of Burn Research, Southwestern Hospital, Third Military Medical University, Chongqing 400038, P. R. China.
Yang
Z
Z
He
B
B
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D002056:Burns / Q000150:complications / Q000188:drug therapy*; D002302:Cardiac Output / Q000187:drug effects; D004285:Dogs; D007958:Leukocyte Count; D017997:Leukotriene C4 / Q000378:metabolism; D008168:Lung / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D008171:Lung Diseases / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D010741:Phospholipases A / Q000187:drug effects / Q000378:metabolism; D054467:Phospholipases A2; D011651:Pulmonary Artery / Q000187:drug effects / Q000503:physiopathology; D015532:Rehydration Solutions / Q000627:therapeutic use*; D012462:Saline Solution, Hypertonic / Q000627:therapeutic use*; D014655:Vascular Resistance / Q000187:drug effects
D015532:Rehydration Solutions; D012462:Saline Solution, Hypertonic; D017997:Leukotriene C4; D010741:Phospholipases A; D054467:Phospholipases A2